IMPACT Therapeutics, Inc., a biotechnology company, researches and develops synthetic lethality (SL)-based precision anti-cancer therapies in China and internationally. The company offers a product, (IMP4297) Senaparib, a PARP1/2 inhibitor that is used for 1L maintenance therapy for ovarian cancer (OC). Its pipeline products includes IMP1734, a next-generation poly (ADP-ribose) polymerase (PARP)1 selective inhibitor evaluated as monotherapy, which is in Phase I/II clinical trial for the treatment of advanced solid tumors; IMP9064, an ataxia telangiectasia and Rad3-related kinase selective inhibitor evaluated as monotherapy, which is in Phase I/II clinical trial for advanced solid tumors; IMP1707, a central nervous system penetrant, PARP1 selective inhibitor, which is in Phase I clinical trial for homologous recombination repair tumors; and IMP7068, and advanced WEE1 inhibitor, which is in Phase I/II clinical trial for advanced solid tumors. The company also develops IMP22, IMP25, IMP08, IMP13, IMP10, IMP27, and IMP32, which are in preclinical stage. The company was founded in 2009 and is based in Shanghai, China.
